Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 5:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 3,095 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: MCG Clear all
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma

NCT03248128
View directory record Official record
Conditions
Asthma
Interventions
FF/VI via ELLIPTA DPI, FF via ELLIPTA DPI
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years to 17 Years
Enrollment
906 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
49
States / cities
Hoover, Alabama • Little Rock, Arkansas • Huntington Beach, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2025 · Synced Oct 24, 2026, 5:35 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Effect of Race on Gonadotropin Responses

NCT00455962
View directory record Official record
Conditions
Premenopause, Healthy
Interventions
Estradiol steroid infusion, Progesterone steroid infusion
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2017 · Synced Oct 24, 2026, 5:35 PM EDT
Completed Phase 3 Interventional Results available

Safety of BTDS in Subjects With Osteoarthritic (OA) Pain of Hip or Knee: A 6-Month Open-label Extension Phase

NCT01141283
View directory record Official record
Conditions
Osteoarthritis
Interventions
Buprenorphine transdermal patch
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years to 75 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
42
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 24, 2026, 5:35 PM EDT
Not listed Phase 4 Interventional

Evaluating Sublingual Dexmedetomidine For Moderate To Severe Agitation In Inpatients With Schizophrenia Or Bipolar Disorder

NCT06093451
View directory record Official record
Conditions
Schizophrenia Agitation, Schizo Affective Disorder, Bipolar Disorder, Dexmedetomidine
Interventions
Dexmedetomidine, Lorazepam 2 MG/ML
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 24, 2026, 5:35 PM EDT
Terminated Phase 2 Interventional Results available

Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma

NCT00001703
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
incomplete Freund's adjuvant, von Hippel-Lindau peptide vaccine
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 25, 2014 · Synced Oct 24, 2026, 5:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Personalized Lifestyle Intervention for Improving Functional Health Outcomes Using N-of-1 Tent-Umbrella-Bucket Design

NCT04005456
View directory record Official record
Conditions
Health, Subjective, Gastrointestinal Dysfunction, Cardiovascular Risk Factor, Autoimmune Diseases, Dental Diseases, Hormone Disturbance, Neurocognitive Dysfunction
Interventions
Supplements and/or medical foods, Behavioral change support program, Food plan
Dietary Supplement · Behavioral · Other
Lead sponsor
Metagenics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Gig Harbor, Washington
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 24, 2026, 5:35 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Assess the Safety & Immunogenicity of Stored Inactivated Influenza H5N1 Virus Vaccine Given With & Without Stored MF59 Adjuvant

NCT02680002
View directory record Official record
Conditions
A/Vietnam/H5N1 Influenza Virus
Interventions
7.5 mcg H5N1 (stored as monobulk), 15 mcg H5N1 (stored as monobulk), 90 mcg H5N1 (stored as monobulk), 90 mcg H5N1 (stored in vials), MF59, MF59 (stored as monobulk)
Biological · Other
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years to 49 Years
Enrollment
422 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
6
States / cities
Atlanta, Georgia • Council Bluffs, Iowa • Lenexa, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Oct 24, 2026, 5:35 PM EDT
Completed Phase 3 Interventional Results available

Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma

NCT00186888
View directory record Official record
Conditions
Retinoblastoma, Retinal Neoplasm
Interventions
Enucleation, Vincristine, Carboplatin, Focal Therapies, External Beam Radiation, Vincristine and Topotecan, Vincristine + Carboplatin + Etoposide, vincristine, cyclophosphamide, and doxorubicin, Vincristine, Carboplatin and Etoposide, Periocular carboplatin, G-CSF
Procedure · Drug · Radiation + 1 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2024
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Oct 24, 2026, 5:35 PM EDT
Terminated Phase 3 Interventional Results available

Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis

NCT01058005
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
BG00002 (natalizumab), interferon beta-1a, glatiramer acetate
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 60 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
19
States / cities
Cullman, Alabama • Phoenix, Arizona • Fort Collins, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2014 · Synced Oct 24, 2026, 5:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of a Nipah Virus Vaccine

NCT04199169
View directory record Official record
Conditions
Nipah Virus Infection
Interventions
HeV-sG-V, Normal Saline Placebo
Biological
Lead sponsor
Auro Vaccines LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
192 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 17, 2022 · Synced Oct 24, 2026, 5:35 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Double Simultaneous Uterotonic Agents Versus Single Agent Regimen to Prevent Early Postpartum Hemorrhage

NCT05245227
View directory record Official record
Conditions
Postpartum Hemorrhage
Interventions
Sublingual Misoprostol, IV Oxytocin
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older · Female only
Enrollment
1,358 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Oct 24, 2026, 5:35 PM EDT
Completed Not applicable Interventional

A 30 Day Acute Efficacy and Safety Study of Chromium Picolinate + Biotin on Glycemic Control in Overweight or Obese Subjects With T2DM

NCT00308451
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Chromium Picolinate (600 mcg Cr+3) + biotin (2 mg)
Drug
Lead sponsor
Nutrition 21, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 29, 2006 · Synced Oct 24, 2026, 5:35 PM EDT
Completed Phase 1 Interventional Results available

Susceptibility of Motor-Evoked Potentials to Varying Targeted Blood Levels of Dexmedetomidine

NCT00671931
View directory record Official record
Conditions
Scoliosis
Interventions
low dexmedetomidine, low propofol, high dexmedetomidine, low propofol, Dexmedetomidine, Dexmedetomidin
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
10 Years to 25 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 23, 2013 · Synced Oct 24, 2026, 5:35 PM EDT
Completed Phase 2 Interventional Results available

Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG

NCT01390402
View directory record Official record
Conditions
Leukemia, Chronic Myelogenous Leukemia
Interventions
Fludarabine, Busulfan, NK cell infusion:, Interleukin-2, Anti-Thymocyte Globulin, Allogeneic related Stem Cell Transplant, Tacrolimus, Methotrexate, G-CSF
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Oct 24, 2026, 5:35 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of MCG for Diagnosing Coronary Heart Disease

NCT00170027
View directory record Official record
Conditions
Myocardial Ischemia
Interventions
Magnetocardiograph
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 15, 2011 · Synced Oct 24, 2026, 5:35 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT02250651
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
Bimatoprost SR, Sham: Applicator Without Needle, Active Comparator: Timolol 0.5%, Timolol Vehicle (placebo)
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
51
States / cities
Dothan, Alabama • Chandler, Arizona • Fayetteville, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Oct 24, 2026, 5:35 PM EDT
Terminated Phase 3 Interventional Results available

A Long-Term Study of the Safety and Tolerability of Repeated Administration of CEP-33457 in Participants With Systemic Lupus Erythematosus

NCT01240694
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
CEP-33457
Drug
Lead sponsor
Cephalon, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
39
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2022 · Synced Oct 24, 2026, 5:35 PM EDT
Completed Phase 2 Interventional Results available

Comparing Pump With Subcutaneous Injection Delivery of PTH 1-34 in the Management of Chronic Hypoparathyroidism

NCT00743782
View directory record Official record
Conditions
Hypoparathyroidism, Hypocalcemia, Autoimmune Polyendocrine Syndrome Type 1, Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Interventions
Synthetic Human Parathyroid Hormone 1-34 pump
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
7 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 24, 2026, 5:35 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650

NCT01455896
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
ITCA 650, ITCA placebo
Drug · Other
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
40 Years and older
Enrollment
4,156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
34
States / cities
Chandler, Arizona • Hayward, California • Long Beach, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2017 · Synced Oct 24, 2026, 5:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Lofexidine ADME & Mass Balance in Volunteers

NCT01310296
View directory record Official record
Conditions
Normal Healthy Volunteers Will be Treated With Lofexidine to Understand the Absolute Bioavailability and Mass Balance Recovery of the Product
Interventions
Lofexidine hydrochloride
Drug
Lead sponsor
USWM, LLC (dba US WorldMeds)
Industry
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Oct 24, 2026, 5:35 PM EDT
Completed Phase 3 Interventional Results available

PEDS-C: Pegylated Interferon +/- Ribavirin for Children With Hepatitis C

NCT00100659
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Pegylated Interferon/ribavirin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
5 Years to 18 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
11
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Oct 24, 2026, 5:35 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and Metformin

NCT00099320
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
21 Years to 75 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
40
States / cities
Birmingham, Alabama • La Jolla, California • San Mateo, California + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced Oct 24, 2026, 5:35 PM EDT
Completed Phase 1 Interventional

ABR-217620 in Combination With Docetaxel in Patients With Advanced Non-small Cell Lung Cancer

NCT00132379
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
ABR-217620, docetaxel
Drug
Lead sponsor
Active Biotech AB
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 27, 2014 · Synced Oct 24, 2026, 5:35 PM EDT
Terminated Phase 3 Interventional

Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Moderate to Severe Cancer Pain

NCT00126789
View directory record Official record
Conditions
Pain, Cancer
Interventions
Fentanyl Transdermal Matrix Patch ZR-02-01
Drug
Lead sponsor
ZARS Pharma Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Loma Linda, California • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 5, 2012 · Synced Oct 24, 2026, 5:35 PM EDT